Search results for: Multi-Indication Medicines
Filter search results
Industrial Policy and the Pharmaceutical Industry
1 January 1995
…— intellectual property protection (the pharmaceutical industry is the most patent intensive of any industrial sector) — and, in most countries, government as a major purchaser of medicines. There is…
Trade Mark Legislation and the Pharmaceutical Industry
1 May 1999
…over the counter (OTC) medicines as well as prescription only medicines. The structure of this report is as follows. Chapter 2 identifies those features of the pharmaceutical industry which set…
To Heal and Harm: An Economic View of Drug Safety
1 December 2003
The aims of this book are to: • provide an historical background to modern pharmaceutical regulation; • summarise available data on the harm caused by medicines; • comment on treatment…
Migraine
1 September 1991
…therapeutic research and the NHS. After a prolonged period in which drug therapy for migraine has made little advance, research has produced promising medicines for the effective treatment of acute…
Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
4 January 2016
…Care Excellence (NICE) to decide which new medicines to recommend for use in… This report details the views of a selection of experts in the fields of health and welfare…
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
1 March 2017
…new treatments for rare and chronically disabling or life-threatening diseases. Marketing authorisation granted to orphan medicinal products (OMPs) is however only the first step; patients have access to medicines once…
The Evolution of US Policy Responses to the Opioid Epidemic
1 March 2020
The ‘opioid epidemic’ in the US is the most recent drug-abuse challenge from the misuse of prescription medicines or the use of illicit drugs. It is a particularly difficult challenge…
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
The National Institute of Health and Care Excellence (NICE) makes recommendations for the use of interventions including medicines in the National Health Service in England based on their clinical and…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and…